Two other potential targets in CLL cells are BAFF-R and BCMA, both activated by the protein BAFF, which is expressed by immunosuppressive cells in the TME in CLL and promotes disease progression and chemotherapy resistance[101]. This evidence concerns the gene TNFRSF17 and B-cell chronic lymphocytic leukemia.